Bristol Myers Squibb Company (NYSE:BMY) Shares Acquired by Mesirow Financial Investment Management Inc.

Key Points

• Mesirow Financial Investment Management Inc. has increased its stake in Bristol Myers Squibb (NYSE:BMY) by 16.7%, now holding 45,545 shares worth approximately $2.78 million.
• Analysts hold a mixed outlook on Bristol Myers Squibb, with recent price targets set between $34.00 and $55.00, and a consensus rating of "Hold."
• Bristol Myers Squibb recently declared a quarterly dividend of $0.62 per share, resulting in an annualized payout of $2.48 and a yield of 5.39%.

Mesirow Financial Investment Management Inc. raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 16.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,545 shares of the biopharmaceutical company's stock after buying an additional 6,526 shares during the period. Mesirow Financial Investment Management Inc.'s holdings in Bristol Myers Squibb were worth $2,778,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Bayforest Capital Ltd grew its holdings in Bristol Myers Squibb by 125.7% during the 1st quarter. Bayforest Capital Ltd now owns 16,656 shares of the biopharmaceutical company's stock valued at $1,016,000 after buying an additional 9,275 shares in the last quarter. Banque Cantonale Vaudoise purchased a new position in shares of Bristol Myers Squibb in the first quarter valued at $11,383,000. Geneos Wealth Management Inc. grew its stake in shares of Bristol Myers Squibb by 0.5% in the 1st quarter. Geneos Wealth Management Inc. now owns 96,397 shares of the biopharmaceutical company's stock worth $5,879,000 after buying an additional 442 shares in the last quarter. N.E.W. Advisory Services LLC purchased a new position in Bristol Myers Squibb in the first quarter worth about $113,000. Finally, Meeder Advisory Services Inc. boosted its holdings in shares of Bristol Myers Squibb by 5.4% in the 1st quarter. Meeder Advisory Services Inc. now owns 36,727 shares of the biopharmaceutical company's stock worth $2,240,000 after purchasing an additional 1,882 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY traded up $1.05 on Monday, reaching $45.28. 7,959,476 shares of the company were exchanged, compared to its average volume of 13,512,480. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The company has a 50-day moving average of $47.51 and a 200-day moving average of $52.23. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The firm has a market cap of $92.16 billion, a price-to-earnings ratio of 18.26, a price-to-earnings-growth ratio of 2.33 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The business's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the business posted $2.07 earnings per share. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.5%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 100.00%.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday. Piper Sandler initiated coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. Citigroup lowered their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research note on Friday. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $57.33.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.